Guilherme Nader-Marta - JoVE Visualize

Showing results (31-40 of 39) with videos related to

Pageof 4

Sort By:

You have reached the last page of results.This site can display upto 39 results.

Breast Cancer Research : BCR|October 7, 2024

Clinical characterization, prognostic, and predictive values of HER2-low in patients with early breast cancer in the PALLAS trial (ABCSG-42/AFT-05/BIG-14-13/PrE0109)Guilherme Nader-Marta, Christian Singer, Dominik Hlauschek, et al.

Cancer|October 24, 2022

A phase 2 study of first-line nivolumab in patients with locally advanced or metastatic cutaneous squamous-cell carcinomaRodrigo R Munhoz, Guilherme Nader-Marta, Veridiana P de Camargo, et al.

Current Oncology (Toronto, Ont.)|September 30, 2021

Brazilian Validation of the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Group (QLG) Computerised Adaptive Tests (CAT) CoreGustavo Nader Marta, Tomás Y T de Souza, Alice R N de Souza E Silva, et al.

Journal of the National Cancer Institute|May 19, 2026

Pregnancy history, recency of childbirth, and outcomes in young women with early-stage breast cancerGuilherme Nader-Marta, Yue Zheng, Shoshana M Rosenberg, et al.

JCO Global Oncology|July 6, 2021

Outcomes and Prognostic Factors in a Large Cohort of Hospitalized Cancer Patients With COVID-19Guilherme Nader Marta, Renata Colombo Bonadio, Odeli Nicole Encinas Sejas, et al.

Nature Medicine|June 25, 2026

Neoadjuvant stereotactic body radiation therapy with durvalumab and oleclumab in ER+HER2- breast cancer: a randomized phase 2 trialAlex De Caluwé, Isabelle Desmoulins, Kim Cao, et al.

Journal of the National Cancer Institute|October 11, 2025

Prognostic value of visually and computationally assessed tumor-infiltrating lymphocytes in early-stage triple-negative breast cancer (TBCRC-030)Guilherme Nader-Marta, Xiangying Chu, Satabhisa Mukhopadhyay, et al.

European Journal of Cancer (Oxford, England : 1990)|August 13, 2023

Association of body mass index with clinicopathological features and survival in patients with primary invasive lobular breast cancerKaren Van Baelen, Ha-Linh Nguyen, Anne-Sophie Hamy-Petit, et al.

Breast Cancer Research and Treatment|July 10, 2026

EVERolimus effectiveness after proGREssion on ENdocrine therapy plus CDK4/6 inhibitor for ER-positive/HER2-negative advanced breast cancer: EVERGREEN studyDiogo Martins-Branco, Soraia Lobo-Martins, Philippe Aftimos, et al.

Pageof 4

Showing results (31-40 of 39) with videos related to

Sort By:

Pageof 4

You have reached the last page of results.This site can display upto 39 results.

Breast Cancer Research : BCR|October 7, 2024

Clinical characterization, prognostic, and predictive values of HER2-low in patients with early breast cancer in the PALLAS trial (ABCSG-42/AFT-05/BIG-14-13/PrE0109)Guilherme Nader-Marta, Christian Singer, Dominik Hlauschek, et al.

Cancer|October 24, 2022

A phase 2 study of first-line nivolumab in patients with locally advanced or metastatic cutaneous squamous-cell carcinomaRodrigo R Munhoz, Guilherme Nader-Marta, Veridiana P de Camargo, et al.

Current Oncology (Toronto, Ont.)|September 30, 2021

Brazilian Validation of the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Group (QLG) Computerised Adaptive Tests (CAT) CoreGustavo Nader Marta, Tomás Y T de Souza, Alice R N de Souza E Silva, et al.

Journal of the National Cancer Institute|May 19, 2026

Pregnancy history, recency of childbirth, and outcomes in young women with early-stage breast cancerGuilherme Nader-Marta, Yue Zheng, Shoshana M Rosenberg, et al.

JCO Global Oncology|July 6, 2021

Outcomes and Prognostic Factors in a Large Cohort of Hospitalized Cancer Patients With COVID-19Guilherme Nader Marta, Renata Colombo Bonadio, Odeli Nicole Encinas Sejas, et al.

Nature Medicine|June 25, 2026

Neoadjuvant stereotactic body radiation therapy with durvalumab and oleclumab in ER+HER2- breast cancer: a randomized phase 2 trialAlex De Caluwé, Isabelle Desmoulins, Kim Cao, et al.

Journal of the National Cancer Institute|October 11, 2025

Prognostic value of visually and computationally assessed tumor-infiltrating lymphocytes in early-stage triple-negative breast cancer (TBCRC-030)Guilherme Nader-Marta, Xiangying Chu, Satabhisa Mukhopadhyay, et al.

European Journal of Cancer (Oxford, England : 1990)|August 13, 2023

Association of body mass index with clinicopathological features and survival in patients with primary invasive lobular breast cancerKaren Van Baelen, Ha-Linh Nguyen, Anne-Sophie Hamy-Petit, et al.

Breast Cancer Research and Treatment|July 10, 2026

EVERolimus effectiveness after proGREssion on ENdocrine therapy plus CDK4/6 inhibitor for ER-positive/HER2-negative advanced breast cancer: EVERGREEN studyDiogo Martins-Branco, Soraia Lobo-Martins, Philippe Aftimos, et al.

Pageof 4